Washington University School of Medicine in St. Louis | Strategic Alliance Partners

December 18, 2024

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

December 10, 2024

After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer

December 02, 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

November 11, 2024

Dr Thaker discusses the rationale for combining relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, and the future of the ROSELLA trial.

November 08, 2024

Premal Thaker, MD, MS, discusses the role of the glucocorticoid receptor pathway and the development of chemoresistance in ovarian cancer.

November 07, 2024

Matthew Powell, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with advanced or recurrent endometrial cancer.

October 31, 2024

Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.

October 21, 2024

Faculty at Washington University School of Medicine in St. Louis have designed a clinical trial development fellowship education program.

September 07, 2024

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

July 18, 2024

Andrew Davis, MD, discusses the use of antibody-drug conjugates in breast cancer, highlighting recent updates with these agents in the treatment paradigm.

June 03, 2024

Olivia Aranha, MD, PhD, discusses data supporting the use of HIPEC for patients with peritoneal carcinomatosis in gastrointestinal malignancies.

June 03, 2024

Michael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making.

May 27, 2024

Two clinical trials for AML or MDS are open and enrolling at Siteman Cancer Center and Washington University School of Medicine in St. Louis.

May 14, 2024

Michael Iglesia, MD, PhD, discusses uncertainties surrounding the selection of second-line treatment approaches in hepatocellular carcinoma.

May 13, 2024

Katrina S. Pedersen, MD, MS, discusses key updates in the therapeutic landscape for patients with molecularly targetable metastatic colorectal cancer.

May 03, 2024

Michael Iglesia, MD, PhD, discusses outcomes from the phase 3 COSMIC-312 trial of first-line cabozantinib plus atezolizumab in hepatocellular carcinoma.

May 02, 2024

Kian-Huat Lim, MD, PhD, discusses the role of multidisciplinary collaboration and clinical trials in the treatment of pancreatic cancer.

April 08, 2024

Premal Thaker, MD, MS, discusses the phase 3 RAMP-301 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer.

April 01, 2024

Katrina S. Pedersen, MD, MS, discusses the evolution of the role of immunotherapy in the treatment of patients with hepatocellular carcinoma.

March 13, 2024

Katrina S. Pedersen, MD, MS, discusses the evolving use of cytoreductive surgery for patients with peritoneal carcinomatosis.